{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Anavex Life Sciences Corp."},"Symbol":{"label":"Symbol","value":"AVXL"},"Address":{"label":"Address","value":"630 5TH AVENUE 20TH FLOOR, NEW YORK, New York, 10111, United States"},"Phone":{"label":"Phone","value":"+1 844 689-3939"},"Industry":{"label":"Industry","value":"Biotechnology: Commercial Physical &amp; Biological Resarch"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases."},"CompanyUrl":{"label":"Company Url","value":"https://www.anavex.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher U. Missling","title":"Chairman, President, CEO &amp; Secretary"},{"name":"Edward R. Hammond","title":"Chief Medical Officer"},{"name":"Stephan Toutain","title":"Chief Operating Officer"},{"name":"Walter E. Kaufmann","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}